½ÃÀ庸°í¼­
»óǰÄÚµå
1640530

ºÏ¹ÌÀÇ ±¤ÇÐ À̹Ì¡ : ½ÃÀå Á¡À¯À² ºÐ¼®, »ê¾÷ µ¿Çâ, ¼ºÀå ¿¹Ãø(2025-2030³â)

North America Optical Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Mordor Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ºÏ¹ÌÀÇ ±¤ÇÐ À̹Ì¡ ½ÃÀåÀº ¿¹Ãø ±â°£ µ¿¾È CAGR 10.2%¸¦ ±â·ÏÇÒ Àü¸ÁÀÔ´Ï´Ù.

North America Optical Imaging-Market-IMG1

ÁÖ¿ä ÇÏÀ̶óÀÌÆ®

  • ±¤ÇÐ À̹Ì¡Àº °¡½Ã±¤, Àڿܼ±, Àû¿Ü¼± µîÀÇ ºñÀü¸® ¹æ»ç¼±À» »ç¿ëÇϱ⠶§¹®¿¡ ȯÀÚÀÇ À¯ÇØ ¹æ»ç¼± ÇÇÆøÀ» ´ëÆø ÁÙÀÏ ¼ö ÀÖÀ¸¹Ç·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ±¤ÇÐ À̹Ì¡Àº X¼±°ú °°Àº Àü¸® ¹æ»ç¼±À» »ç¿ëÇÏ´Â ±â¼úº¸´Ù ÈξÀ ¾ÈÀüÇϱ⠶§¹®¿¡ Áúº´ ÁøÇà ¹× Ä¡·á °á°ú¸¦ ¸ð´ÏÅ͸µÇÏ´Â µ¥ Áö¼ÓÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • Á¶»ç Áö¿ª¿¡¼­´Â »ý¸í°úÇÐ ºÐ¾ß¿¡ ´ëÇÑ ÅõÀÚ, R&D Ȱµ¿, ±â¼ú Áøº¸µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 2¿ù, BTR(Boston Technology Research)°ú SaMD´Â ½Ã¸®Áî A ÀÚ±Ý Á¶´Þ ¶ó¿îµå¿¡¼­ 1,500¸¸ ´Þ·¯ÀÇ Á¶´ÞÀ» ¹ßÇ¥Çß½À´Ï´Ù.
  • À§ ÀÚ±Ý Á¶´ÞÀº ¼ÒºñÀÚ°¡ ±âÁ¸ ±â¼ú¿¡¼­ ½Å±â¼ú·ÎÀÇ ÀüȯÀ» Ã˱¸ÇÏ´Â FDA ÁöħÀ» ÁؼöÇÒ Áغñ°¡ µÇ¾úÀ½À» ½Ã»çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ °³¹ßÀº ±¤ÇÐ À̹Ì¡°ú °°Àº ½Å±â¼úÀÇ Ã¤ÅÃÀ» °¡¼ÓÈ­ÇÔÀ¸·Î½á ¿¬±¸ ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù.
  • ¶ÇÇÑ, 2021³â 1¿ù, CARB-X´Â ÆÐÇ÷ÁõÀÇ À§ÇèÀ» Áø´ÜÇϱâ À§ÇÑ »õ·Î¿î ±¤¼¶À¯ ±â¼ú °³¹ßÀ» À§ÇØ ¹Ì±¹ÀÇ »ý¸í°øÇÐ ±â¾÷ÀÎ Accelerate Diagnostics¿¡ 57¸¸ 8,000´Þ·¯¸¦ ÅõÀÚÇß½À´Ï´Ù.
  • ¶ÇÇÑ, ±¤ÇÐ À̹Ì¡Àº ´Ù¾çÇÑ ¿¬ºÎ Á¶Á÷ÀÇ Æ¯¼ºÀ» °áÁ¤ÇÏ´Â µ¥ À¯¿ëÇÕ´Ï´Ù. ¿¬ºÎ Á¶Á÷¿¡ µû¶ó ºûÀÇ Èí¼ö³ª »ê¶õÀÌ ´Ù¸£±â ¶§¹®¿¡ ±¤ÇÐ À̹Ì¡¿¡ ÀÇÇØ Àå±â³ª Á¶Á÷ÀÇ ±â´É ÀÌ»óÀÇ Á¶±â ÁöÇ¥°¡ µÇ´Â ´ë»ç ÀÌ»óÀ» °ËÃâÇÒ ¼ö ÀÖ½À´Ï´Ù. ±¤ÇÐ À̹Ì¡À» ´Ù¸¥ À̹Ì¡ ±â¼ú°ú °áÇÕÇÏ¸é º¹ÀâÇÑ ½ÇÇèÀ» ¼öÇàÇÏ´Â ÀÓ»óÀÇ¿Í ¿¬±¸ÀÚ¿¡°Ô ´õ ¸¹Àº Á¤º¸¸¦ Á¦°øÇÒ ¼ö ÀÖ½À´Ï´Ù. ±¤ÇÐ À̹Ì¡ÀÌ Á¦°øÇÏ´Â ÀÌ·¯ÇÑ ÀåÁ¡Àº ¿¬±¸ ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
  • ±×·¯³ª COVID-19 ÆÒµ¥¹Í ¶§¹®¿¡ Áö¿ª °Ç°­ °ü¸® ½Ã¼³Àº ¸ÅÀÏ ¹æ¹®ÇÏ´Â ¸¹Àº ȯÀÚµé·Î ¸¶ºñµÇ¾úÀ¸¸ç ¸ðµç ±Ô¸ðÀÇ ÀÇ·á ÇöÀåÀº ¸¹Àº ºÎ´ãÀ» ¹Þ¾Ò½À´Ï´Ù. ÆÒµ¥¹ÍÀº ¶ÇÇÑ ÀÇ»ç ¹× ÀÇ·áÀü¹®°¡°¡ »çȸÀû °Å¸®¸¦ À¯ÁöÇÒ Çʿ伺À» ³ô¿´½À´Ï´Ù. ÆÒµ¥¹Í ¶§¹®¿¡ ¸¹Àº ¿µ»ó Áø´Ü ºÎ¼­´Â ¿µ»ó Áø´Ü »ç·Ê ¼ö°¡ ±Þ°¨Çß½À´Ï´Ù.
  • °Ô´Ù°¡ ¾ö°ÝÇÑ ±ÔÁ¦ ½ÂÀÎ ÀýÂ÷, °í°¡ÀÇ Àåºñ ºñ¿ë, ÀÚ°ÝÀ» °®Ãá Àη ºÎÁ·, ±¤ÇÐ À̹Ì¡ ÀýÂ÷¿¡ ´ëÇÑ ºÒÃæºÐÇÑ Áö¿øÀº Á¶»ç ½ÃÀåÀÇ ¼ºÀåÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ±¤ÇÐ À̹Ì¡ ½ÃÀå µ¿Çâ

Á¾¾çÇп¡¼­ ±¤ÇÐ À̹Ì¡ÀÌ Å« ¼ºÀåÀ» ÀÌ·ê Àü¸Á

  • ¹Ì±¹ ±¹¸³¾Ï ¿¬±¸¼Ò(National Cancer Institute)¿¡ µû¸£¸é, ¹Ì±¹¿¡¼­ °¡Àå ¸¹ÀÌ ¹ß»ýÇÏ´Â ¾ÏÀº À¯¹æ¾Ï, Æó¾Ï, ±â°üÁö¾Ï, Àü¸³¼±¾Ï, °áÀå ¹× Á÷Àå¾Ï, ÇÇºÎ Èæ»öÁ¾, ¹æ±¤¾Ï, ºñÈ£ÁöŲ ¸²ÇÁÁ¾, ½ÅÀå ¹× ½Å¿ì¾Ï, Àڱ󻸷¾ÏÀÔ´Ï´Ù.
  • ¶ÇÇÑ ºÏ¹Ì Àεð¾Ö³ªÀÇ ÆÛµà ´ëÇÐÀÇ ¿¬±¸ÀÚµéÀº ¿Ü°úÀǻ簡 ½ÅüÀÇ ¾Ç¼º Á¾¾çÀ» ´õ Á¤È®ÇÏ°Ô ¸ÅÇÎÇÏ°í Æ¯Á¤ Áúº´ÀÌ ³ú Ȱµ¿¿¡ ¾î¶»°Ô ¿µÇâÀ» ¹ÌÄ¡´ÂÁö ÀÌÇØÇÏ´Â µ¥ µµ¿òÀ» ÁÖ±â À§ÇØ ±¤ÇÐ À̹Ì¡À» »ç¿ëÇÏ´Â ÀåÄ¡¸¦ °³¹ßÇß½À´Ï´Ù. Çü±¤ À̹Ì¡Àº ºûÀÌ Å©°Ô ºÐ»êµÇ¾î ¿Ü°ú Àǻ簡 ¾ò´Â Á¤º¸ÀÇ ¾çÀ» Á¦ÇÑÇÏÁö¸¸ ÆÛµà ´ëÇÐÀÇ ±â¼úÀº ÀÌ ¹®Á¦¸¦ ÇØ°áÇÕ´Ï´Ù. ÀÌ ±â¼úÀ» ÅëÇØ ¿Ü°úÀÇ»ç´Â Á¾¾ç ¹× ³ú¼¼Æ÷ Ȱµ¿¿¡ ´ëÇÑ º¸´Ù Á¤È®ÇÑ Á¤º¸¸¦ ¾òÀ» ¼ö ÀÖ¾î ȯÀÚÀÇ °á°ú¸¦ Çâ»ó½Ãų ¼ö ÀÖ½À´Ï´Ù.
  • ±¤ÇÐ À̹Ì¡Àº ¾ÏÀ» ºñħ½ÀÀûÀ¸·Î °ËÃâÇϱâ À§ÇÑ ºü¸£°í, Àú·ÅÇϸç, °¨µµ ³ôÀº À̹Ì¡ ¹æ½ÄÀÔ´Ï´Ù. ±¤ÇÐ Á¶¿µÁ¦¸¦ »ç¿ëÇÏ¿© ¾Ï Á¶Á÷ÀÇ °æ°è¸¦ ¸íÈ®È÷ ÇÔÀ¸·Î½á ¿Ü°úÀÇ»ç´Â Á¤»ó Á¶Á÷°ú Á¾¾ç Á¶Á÷À» º¸´Ù Àß ±¸º°ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿Ü°úÀǻ簡 ÀǵµÇÏÁö ¾Ê°í °Ç°­ÇÑ Á¶Á÷À» ÀýÁ¦ÇÏ´Â °ÍÀ» ÇÇÇÏ°í ¾Ç¼º Á¶Á÷À» ÃÖ´ëÇÑ Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • µÎ°æºÎ¾ÏÀº ÃÖ±Ù ¸î ³â µ¿¾È Àΰ£ÀÇ °Ç°­¿¡ ½É°¢ÇÑ À§ÇùÀ̵Ǿú½À´Ï´Ù. ¼ö¼úÀÌ µÎ°æºÎ¾Ï ȯÀÚ¿¡ ´ëÇÑ Á¦1¼±ÅÃÀÇ Ä¡·á¹ýÀÎ °Í¿¡´Â º¯ÇÔÀÌ ¾øÁö¸¸, µÎ°æºÎ ¿µ¿ª¿¡¼­´Â ÀýÁ¦ °¡´ÉÇÑ Á¶Á÷·®ÀÌ ÇÑÁ¤µÇ¾î ÀÖ°í ÇØºÎÇÐÀû ±¸Á¶µµ º¹ÀâÇϱ⠶§¹®¿¡ ¿Ü°úÀÇ»ç´Â ±¤¹üÀ§ÇÑ ÀýÁ¦¿Í ȯÀÚÀÇ »îÀÇ Áú Çâ»ó »çÀÌ¿¡¼­ Ç×»ó °í¹ÎÇϰí ÀÖ½À´Ï´Ù.
  • Àü¾Ï¼º º´º¯ÀÇ Á¶±â ¹ß°ß°ú Ä¡·á, Àϰý ÀýÁ¦ Áß ¼ö¼ú ´ÜºÎÀÇ ½Ç½Ã°£ »ýü ³» °ËÃâÀº Á¤»ó Á¶Á÷ÀÇ ÀýÁ¦¸¦ ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ±¤ÇÐ Çϵå¿þ¾î¿Í ½Ã¾àÀÇ °³¹ß·Î µÎ°æºÎ Á¾¾çÇÐ ÀÌÇØµµ°¡ ³ô¾ÆÁö°í Ŭ¸®´ÐÀ̳ª ¼ö¼ú½Ç¿¡¼­ ½Ç½Ã°£ Àü¾Ï¼º Á¾¾çÀ̳ª ¾ÏÀÇ À̹Ì¡¿¡ Ź¿ùÇÑ ¼Ö·ç¼ÇÀÌ Åº»ýÇϰí ÀÖ½À´Ï´Ù.

¾È°ú ºÐ¾ß°¡ Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ Àü¸Á

  • ¸Á¸·ÀÇ °íÇØ»óµµ ´Ü¸é ¿µ»óÀ» ¾ò´Â µ¥ »ç¿ëµÇ´Â ºñħ½ÀÀû À̹Ì¡ ±â¼úÀÎ ºû°£¼·´ÜÃþÃÔ¿µÀÇ Àα⠱޻ó½Â°ú Áö¿ª ³ëÀÎ Àα¸ Áõ°¡¿¡ µû¸¥ ¾ÈÁúȯÀÇ À¯º´·ü Áõ°¡°¡ Á¶»ç ´ë»ó ½ÃÀåÀÇ ¼ºÀåÀ» µÞ¹ÞħÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • ¹Ì±¹ Áúº´ ¿¹¹æ°ü¸®¼¾ÅÍ(CDC)°¡ Á¦°øÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ÀϹÝÀûÀÎ ¾ÈÁúȯÀ¸·Î ±¼ÀýÀÌ»ó, ³ì³»Àå, ³ëȭȲ¹Ýº¯¼º, ´ç´¢º´¸Á¸·Áõ, ¹é³»Àå µîÀÌ ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ½Ç¸í ¿¹¹æ°ú ½Ã·Â º¸È£¸¦ ¸ñÀûÀ¸·Î ÇÏ´Â À¯¸íÇÑ ´« °Ç°­ ¹× ¾ÈÀü ÀÚ¿øºÀ»ç ´Üü Prevent Blindness¿¡ µû¸£¸é, 330¸¸¸íÀÇ ¹Ì±¹ÀÎÀÌ °³¹æ°¢ ³ì³»ÀåÀ» ¾Î°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 10¿ù ¸¸¼º Áúȯ Ä¡·á¸¦ À§ÇÑ À¯ÀüÀÚ Ä¡·á¿¡ Á¾»çÇÏ´Â »ý¸í °øÇÐ ±â¾÷ÀÎ Nanoscope Technologies LLC´Â Àΰø ±â°è¼ö¿ëä³Î(EMC)À» ÀÌ¿ëÇÑ ³ì³»Àå Ä¡·áÀÇ ÁøÀüÀ» À§ÇØ NIH¿¡¼­ 150¸¸ ´Þ·¯ÀÇ SBIR Direct-to-Phase II º¸Á¶±ÝÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.
  • ¶ÇÇÑ ¾È°ú ¾÷°è¿¡¼­´Â Áø´Ü ±â¼ú¿¡ AI¸¦ µµÀÔÇÏ´Â ¿òÁ÷ÀÓÀÌ È°¹ßÇØÁö°í ÀÖ½À´Ï´Ù. Àΰ£ÀÇ ´ÙÃþ ½Å°æ°è¿¡ ÈùÆ®¸¦ ¾ò¾î AI´Â ½Ã°¢°ú û°¢ ÀÎ½Ä ÀÛ¾÷À» Å©°Ô °³¼±Çß½À´Ï´Ù. AI´Â ´Ù¾çÇÑ ÀÛ¾÷¿¡¼­ Á¾ÇÕÀûÀÌ°í ½Å¼ÓÇÏ¸ç ºñħ½ÀÀûÀ¸·Î µðÁöÅÐ µ¥ÀÌÅ͸¦ °Ë»çÇÒ ¼ö ÀÖ½À´Ï´Ù.

ºÏ¹ÌÀÇ ±¤ÇÐ À̹Ì¡ »ê¾÷ °³¿ä

ºÏ¹ÌÀÇ ±¤ÇÐ À̹Ì¡ ½ÃÀåÀº Àû´çÈ÷ ´ÜÆíÈ­µÇ¾î ÀÖÀ¸¸ç, Carl Zeiss Meditec AG, ASE Optics Inc., Cytoviva Inc., Heidelberg Engineering Inc. µîÀÇ À¯¸íÇÑ ±â¾÷ÀÌ ÀÖ½À´Ï´Ù. °¢ ȸ»ç´Â ±â¼ú·Â°ú ¾÷°è °æÇèÀ» Ȱ¿ëÇÏ¿© º¹ÀâÇÑ ¹®Á¦¿¡ ´ëÀÀÇϴ ÷´Ü Á¦Ç°À» Çõ½ÅÇÏ°í °í°´ ±â¹ÝÀ» ´Ù¾çÈ­ÇÏ¿© º¸´Ù ³ÐÀº Áö¿ªÀ¸·Î È®ÀåÇØ¾ß ÇÕ´Ï´Ù.

  • 2022³â 10¿ù, Teledyne Technologies Incorporated´Â ¿ÏÀü ÀÚȸ»ç¿¡ ÀÇÇÑ ETM-Electromatic Incorporated(ÀÌÇÏ "ETM") Àμö¸¦ ¹ßÇ¥Çß½À´Ï´Ù. ͏®Æ÷´Ï¾ÆÁÖ ´º¾îÅ©¿¡ º»»ç¸¦ µÐ ETMÀº ¾Ï Ä¡·á, ¹æÀ§, ¿¢½º·¹ÀÌ º¸¾ÈÀ» À§ÇÑ °íÃâ·Â ¸¶ÀÌÅ©·ÎÆÄ ¹× °í¿¡³ÊÁö ¿¢½º·¹ÀÌ ¼­ºê½Ã½ºÅÛÀ» Á¦Á¶ÇÕ´Ï´Ù. TeledyneÀº ¶ÇÇÑ ETMÀÇ °è¿­»ç¿Í ±× ¼ÒÀ¯ÀڷκÎÅÍ ETM Àü¿ë Á¦Á¶ °øÀåÀ» ÃëµæÇÏ¿´½À´Ï´Ù. ETMÀº ÇコÄɾî À̹Ì¡ »ç¾÷°ú ¹æÀ§ÀüÀÚ »ç¾÷¿¡ ¸íÈ®ÇÑ ºÎ°¡°¡Ä¡¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • 2021³â 1¿ù, Olympus Corporation´Â À̹Ì¡ ºÎ¹®À» Japan Industrial Partners Inc¿¡ ¸Å°¢Çß½À´Ï´Ù. ¾çÃøÀÌ ¼­¸íÇÑ ¹ýÀû °è¾à¼­°¡ ÃÖÁ¾ ¾çµµ Áõ¼­°¡ µÇ¾ú½À´Ï´Ù. ¾çµµ ÈÄ OM Digital Solutions Co., Ltd.´Â OlympusÀÇ À̹Ì¡ ºÎ¹®À» ÀμöÇÏ°Ô µË´Ï´Ù.
  • 2021³â 1¿ù Leica Microsystems´Â ÷´Ü °øÃÊÁ¡ Çö¹Ì°æ°ú ±¤½Ã¾ß Çö¹Ì°æ ½Ã½ºÅÛÀ» °®Ãá À̹Ì¡ Àü¿ë Çãºê Á¦°øÀ» À§ÇØ Imperial College¿Í ±¤ÇÐ À̹Ì¡ ¹× ±× ¿¬±¸ ±â¼ú Çõ½Å Á¦ÈÞ¸¦ ¹ßÇ¥Çß½À´Ï´Ù.

±âŸ ÇýÅÃ

  • ¿¢¼¿ Çü½Ä ½ÃÀå ¿¹Ãø(ME) ½ÃÆ®
  • 3°³¿ù°£ ¾Ö³Î¸®½ºÆ® Áö¿ø

¸ñÂ÷

Á¦1Àå ¼­·Ð

  • Á¶»çÀÇ ÀüÁ¦Á¶°Ç°ú ½ÃÀå Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå °³¿ä
  • »ê¾÷ ¹ë·ùüÀÎ ºÐ¼®
  • ¾÷°èÀÇ ¸Å·Âµµ - Porter's Five Forces ºÐ¼®
    • °ø±Þ±â¾÷ÀÇ Çù»ó·Â
    • ±¸¸ÅÀÚÀÇ Çù»ó·Â
    • ½Å±Ô ÁøÀÔ¾÷ÀÚÀÇ À§Çù
    • ´ëüǰÀÇ À§Çù
    • °æÀï ±â¾÷°£ °æÀï °ü°è
  • ±â¼ú ½º³À¼¦
  • ½ÃÀå¿¡ ´ëÇÑ COVID-19ÀÇ ¿µÇâ Æò°¡

Á¦5Àå ½ÃÀå ¿ªÇÐ

  • ÃËÁø¿äÀÎ
    • ¾È°ú¿ë ¼ö¿ä Áõ°¡
    • ±â¼úÀÇ Áøº¸
  • ¾ïÁ¦¿äÀÎ
    • ³ôÀº ÀåÄ¡ Ãʱ⠺ñ¿ë

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

  • ±â¼úº°
    • ±¤À½Çâ´ÜÃþÃÔ¿µ
    • ºû°£¼·´ÜÃþÃÔ¿µ(OCT)
    • Ãʺб¤À̹Ì¡
    • ±ÙÀû¿Ü¼±ºÐ±¤¹ý
  • Á¦Ç°º°
    • À̹Ì¡ ½Ã½ºÅÛ
    • Á¶¸í ½Ã½ºÅÛ
    • ·»Áî
    • ±¤ÇÐ À̹Ì¡ ¼ÒÇÁÆ®¿þ¾î
    • ±âŸ Á¦Ç°
  • ¿ëµµ ºÐ¾ßº°
    • ¾È°ú
    • Á¾¾ç
    • ½ÉÀåÇÐ
    • ÇǺΰú
    • ½Å°æÇÐ
    • Ä¡°ú
    • ±âŸ ¿ëµµ ºÐ¾ß
  • ÃÖÁ¾ »ç¿ëÀÚ »ê¾÷º°
    • º´¿ø ¹× Áø·á¼Ò
    • Á¶»ç ¹× Áø´Ü ¿¬±¸¼Ò
    • Á¦¾à¾÷°è
    • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
  • ±¹°¡º°
    • ¹Ì±¹
    • ij³ª´Ù

Á¦7Àå °æÀï ±¸µµ

  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Bruker Corporation
    • Carl Zeiss AG
    • Leica Microsystems
    • CytoViva Inc.
    • Abbott Laboratories
    • Topcon Corporation
    • Headwall Photonics Inc.
    • Perkinelmer Inc.
    • Agfa-Gevaert NV
    • Heidelberg Engineering
    • Olympus Corporation

Á¦8Àå ÅõÀÚ ºÐ¼®

Á¦9Àå Àå·¡ÀÇ Àü¸Á

CSM 25.02.20

The North America Optical Imaging Market is expected to register a CAGR of 10.2% during the forecast period.

North America Optical Imaging - Market - IMG1

Key Highlights

  • Optical imaging is gaining popularity as it employs non-ionizing radiation, such as visible, ultraviolet, and infrared light, which considerably minimizes patient exposure to hazardous radiation. Optical imaging can be used for repeated procedures to monitor the progression of a disease or the results of treatment, as it is far safer than techniques that employ ionizing radiation, such as X-rays.
  • The region is also witnessing a rise in investments, R&D activities, and technological advancements in the life sciences sector. For instance, in February 2022, BTR (Boston Technology Research) and SaMD announced raising USD 15 million in a Series A funding round.
  • The funding would ensure that customers are prepared for the FDA's anticipated guidance to incentivize a move from traditional methods to new technologies. Such developments are likely to boost the growth of the market studied by accelerating the adoption of new technologies like optical imaging.
  • Additionally, in January 2021, CARB-X awarded USD 578,000 to Accelerate Diagnostics, a USA-based biotech company, for developing new fiber optic technology to diagnose sepsis or the risk of sepsis.
  • Further, optical imaging is beneficial for determining various soft tissue properties. As different soft tissues absorb and scatter light differently, optical imaging can detect metabolic abnormalities that are early indicators of abnormal organ and tissue functioning. Optical imaging can be combined with other imaging techniques to provide more information to clinicians and researchers working on complex experiments. Such advantages provided by optical imaging are expected to fuel the growth of the market studied.
  • However, due to the COVID-19 pandemic, medical practices of all sizes were under tremendous strain as healthcare facilities in the region were overwhelmed by the large number of patients who visited them daily. The pandemic also increased the need for physicians and other healthcare professionals to maintain social distancing. Due to the pandemic, many imaging and diagnostic departments saw a sharp decline in optical imaging case volumes.
  • Additionally, stringent regulatory approval procedures, hefty instrument costs, a scarcity of qualified operators, and insufficient reimbursements for optical imaging procedures hinder the growth of the market studied.

North America Optical Imaging Market Trends

Optical Imaging in Oncology is Expected to Witness Significant Growth

  • According to National Cancer Institute, the most common cancers in the United States (listed in descending order) are breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer.
  • Additionally, researchers at Purdue University in Indiana, North America, developed equipment that uses optical imaging to assist surgeons in better mapping out bodily malignancies and understanding how specific diseases affect brain activity. The light becomes greatly dispersed during fluorescence imaging, limiting the amount of information a surgeon can obtain. Purdue technology solves this problem. This technique gives surgeons more precise information about tumors and brain cell activity, which can enhance patient outcomes.
  • Optical imaging is a fast, inexpensive, and sensitive imaging approach for the non-invasive detection of cancers. Defining the margins of cancerous tissue using optical contrast agents can allow the surgeon to distinguish between normal and tumor tissue better. It also allows surgeons to avoid the unintentional removal of healthy tissue and prevent failure to maximize the removal of malignant tissue.
  • Moreover, head and neck cancers have become a significant threat to human health in recent years. While surgery remains the first-line treatment option for patients with head and neck cancer, the limited resectable tissue mass and complex anatomy structures in the head and neck region put surgeons in a predicament between extensive resection and a better quality of life for the patient, as removing too much may negatively impact the patient's quality of life, and pulling too little may cause cancer to reoccur.
  • Early detection and treatment of pre-malignant lesions and real-time in vivo detection of surgical margins during en-bloc resection could reduce the resection of normal tissues. Developments in optical hardware and reagents have created exceptional prospects for real-time pre-malignancies and cancer imaging in the clinic or operating room, with an understanding of head and neck oncology.

Ophthalmology Segment is Expected to Hold a Significant Market Share

  • The soaring popularity of Optical Coherence Tomography, a non-invasive imaging technology used to obtain high-resolution cross-sectional images of the retina, and the rising prevalence of eye disorders as the regional senior population grows, are expected to aid the growth of the market studied.
  • Based on the data provided by the Centers for Disease Control and Prevention (CDC), in the United States, common eye disorders include refractive errors, glaucoma, age-related macular degeneration, diabetic retinopathy, and cataracts.
  • Additionally, 3.3 million Americans have open-angle glaucoma, according to Prevent Blindness, a prominent volunteer eye health and safety organization devoted to preventing blindness and preserving sight. For instance, in October 2022, Nanoscope Technologies LLC, a biotechnology company working on gene therapies for the treatment of chronic diseases, announced that it had been awarded a USD 1.5 million SBIR Direct-to-Phase II grant from the NIH in support of its advancement of glaucoma therapy using engineered mechanosensitive channels (EMC).
  • In addition, the ophthalmic industry is seeing an increase in the incorporation of AI into diagnostic techniques. Inspired by the human multilayered neuronal system, AI has significantly improved some visual and auditory recognition tasks. AI can comprehensively, quickly, and non-invasively examine digital data in various tasks.

North America Optical Imaging Industry Overview

The North American optical imaging market is moderately fragmented, with prominent players like Carl Zeiss Meditec AG, ASE Optics Inc., Cytoviva Inc., Heidelberg Engineering Inc., etc. The companies must leverage their technological capabilities and industry experience to innovate advanced products that cater to complex issues to diversify their customer base and capture a wider geographic area.

  • In October 2022, Teledyne Technologies Incorporated announced the acquisition of ETM-Electromatic Inc. ("ETM") by a wholly-owned subsidiary. ETM, based in Newark, California, creates high-power microwave and high-energy X-ray subsystems for cancer treatment, defense, and X-ray security. Teledyne will also acquire ETM's purpose-built manufacturing plant from an affiliate of ETM and its owners. ETM adds a distinct value to its healthcare imaging and defense electronics businesses.
  • In January 2021, Olympus Corporation sold its imaging division to Japan Industrial Partners Inc. A legal agreement that both parties signed served as the basis for the final transfer. Following the handover, OM Digital Solutions Corporation took over Olympus' Imaging division.
  • In January 2021, Leica Microsystems announced a partnership with Imperial College in optical imaging and its use in research and innovation to set up a dedicated imaging hub equipped with advanced confocal and widefield microscopy systems.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET INSIGHT

  • 4.1 Market Overview
  • 4.2 Industry Value Chain Analysis
  • 4.3 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.3.1 Bargaining Power of Suppliers
    • 4.3.2 Bargaining Power of Buyers
    • 4.3.3 Threat of New Entrants
    • 4.3.4 Threat of Substitute Products
    • 4.3.5 Intensity of Competitive Rivalry
  • 4.4 Technology Snapshot
  • 4.5 Assessment of the Impact of COVID-19 on the Market

5 MARKET DYNAMICS

  • 5.1 Market Drivers
    • 5.1.1 Rising Demand for Ophthalmology
    • 5.1.2 Advancements in Technology
  • 5.2 Market Restraints
    • 5.2.1 High Initial Cost of the Equipment

6 MARKET SEGMENTATION

  • 6.1 By Technology
    • 6.1.1 Photoacoustic Tomography
    • 6.1.2 Optical Coherence Tomography
    • 6.1.3 Hyperspectral Imaging
    • 6.1.4 Near-infrared Spectroscopy
  • 6.2 By Product
    • 6.2.1 Imaging Systems
    • 6.2.2 Illumination Systems
    • 6.2.3 Lenses
    • 6.2.4 Optical Imaging Software
    • 6.2.5 Other Products
  • 6.3 By Application Area
    • 6.3.1 Ophthalmology
    • 6.3.2 Oncology
    • 6.3.3 Cardiology
    • 6.3.4 Dermatology
    • 6.3.5 Neurology
    • 6.3.6 Dentistry
    • 6.3.7 Other Application Areas
  • 6.4 By End-user Industry
    • 6.4.1 Hospitals and Clinics
    • 6.4.2 Research and Diagnostic Laboratories
    • 6.4.3 Pharmaceutical Industry
    • 6.4.4 Biotechnology Companies
  • 6.5 By Country
    • 6.5.1 United States
    • 6.5.2 Canada

7 COMPETITIVE LANDSCAPE

  • 7.1 Company Profiles
    • 7.1.1 Bruker Corporation
    • 7.1.2 Carl Zeiss AG
    • 7.1.3 Leica Microsystems
    • 7.1.4 CytoViva Inc.
    • 7.1.5 Abbott Laboratories
    • 7.1.6 Topcon Corporation
    • 7.1.7 Headwall Photonics Inc.
    • 7.1.8 Perkinelmer Inc.
    • 7.1.9 Agfa-Gevaert NV
    • 7.1.10 Heidelberg Engineering
    • 7.1.11 Olympus Corporation

8 INVESTMENT ANALYSIS

9 FUTURE OUTLOOK

ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦